The results revealed that LOX-targeted nanoparticles were more effective when compared to a soluble anti-LOX antibody (which was not accompanied by nanoparticles) in vitro in mouse mammary cancer cells and in vivo in a mouse breast cancer xenograft model 144. Here, LOX is linked to breast carcinoma.